Cardiovascular magnetic resonance of mitral valve length in hypertrophic cardiomyopathy

Show full item record



Permalink

http://hdl.handle.net/10138/164664

Citation

Tarkiainen , M , Sipola , P , Jalanko , M , Helio , T , Laine , M , Jarvinen , V , Hayrinen , K , Lauerma , K & Kuusisto , J 2016 , ' Cardiovascular magnetic resonance of mitral valve length in hypertrophic cardiomyopathy ' , Journal of Cardiovascular Magnetic Resonance , vol. 18 , 33 . https://doi.org/10.1186/s12968-016-0250-5

Title: Cardiovascular magnetic resonance of mitral valve length in hypertrophic cardiomyopathy
Author: Tarkiainen, Mika; Sipola, Petri; Jalanko, Mikko; Helio, Tiina; Laine, Mika; Jarvinen, Vesa; Hayrinen, Kaisu; Lauerma, Kirsi; Kuusisto, Johanna
Contributor: University of Helsinki, Department of Medicine
University of Helsinki, Kardiologian yksikkö
University of Helsinki, Clinicum
Date: 2016-06-04
Language: eng
Number of pages: 10
Belongs to series: Journal of Cardiovascular Magnetic Resonance
ISSN: 1097-6647
URI: http://hdl.handle.net/10138/164664
Abstract: Background: Previous data suggest that mitral valve leaflets are elongated in hypertrophic cardiomyopathy (HCM), and mitral valve leaflet elongation may constitute a primary phenotypic expression of HCM. Our objective was to measure the length of mitral valve leaflets by cardiovascular magnetic resonance (CMR) in subjects with HCM caused by a Finnish founder mutation in the myosin-binding protein C gene (MYBPC3-Q1061X), carriers of the same mutation without left ventricular hypertrophy, as well as in unselected consecutive patients with HCM, and respective controls. Methods: Anterior mitral valve leaflet (AML) and posterior mitral valve leaflet (PML) lengths were measured by CMR in 47 subjects with the Q1061X mutation in the gene encoding MYBPC3 and in 20 healthy relatives without the mutation. In addition, mitral valve leaflet lengths were measured by CMR in 80 consecutive non-genotyped patients with HCM in CMR and 71 age-and gender-matched healthy subjects. Results: Of the subjects with the MYBPC-Q1016X mutation, 32 had left ventricular hypertrophy (LVH, LV maximal wall thickness >= 13 mm in CMR) and 15 had no hypertrophy. PML was longer in patients with the MYBPC3-Q1061X mutation and LVH than in controls of the MYBPC group (12.8 +/- 2.8 vs 10.6 +/- 1.9 mm, P = 0.013), but the difference between the groups was not statistically significant when PML was indexed for BSA (P = 0.066), or when PML length was adjusted for BSA, age, gender, LV mass and ejection fraction (P = 0.195). There was no significant difference in the PML length in mutation carriers without LVH and controls (11.1 +/- 3.4 vs 10.6 +/- 1.9, P = 0.52). We found no difference in AML lengths between the MYBPC mutation carriers with or without hypertrophy and controls. In 80 consecutive non-genotyped patients with HCM, there was no difference either in AML or PML lengths in subjects with HCM compared to respective control subjects. Conclusions: In subjects with HCM caused by the Q1061X mutation in the MYBPC3 gene, the posterior mitral valve leaflets may be elongated, but mitral valve elongation does not constitute primary phenotypic expression of the disease. Instead, elongated mitral valve leaflets seem to be associated with body size and left ventricular remodeling.
Subject: Cardiomyopathy
Hypertrophic
Mitral valve
Cardiovascular magnetic resonance
BINDING-PROTEIN-C
ALPHA-TROPOMYOSIN GENE
ASP175ASN MUTATION
FOUNDER MUTATIONS
EASTERN FINLAND
HAPLOINSUFFICIENCY
PATHOPHYSIOLOGY
IMPAIRMENT
EXPRESSION
PROLAPSE
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
art_3A10.1186_2Fs12968_016_0250_5.pdf 800.1Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record